CJC-1295 DAC

CJC-1295 DAC is reported to act through the GHRH receptor on pituitary cells. The source links this receptor activation to endogenous growth hormone release and subsequent IGF-1 production by the liver. Its modified GRF(1-29) structure includes four amino acid substitutions associated with resistance to DPP-IV degradation, and the DAC group is described as enabling albumin binding, which slows clearance and extends activity compared with short-lived GHRH fragments.

The source identifies the main human evidence as an early study by Teichman and colleagues published in 2006 in the Journal of Clinical Endocrinology and Metabolism. In healthy adults, a single subcutaneous dose was associated with GH increases of about 2 to 10 fold and IGF-1 increases of about 1.5 to 3 fold. The source reports GH elevation for at least 6 days, IGF-1 elevation for 9 to 11 days, and sustained above-baseline IGF-1 for up to 28 days with repeated dosing. It also reports an estimated half-life of about 5.8 to 8.1 days and no serious adverse reactions in that short trial. Beyond the human pharmacology data, the source mentions animal work in GHRH knockout mice in which once-daily CJC-1295 normalized growth. The source also states that original sponsor development stopped, and that a related long-acting analog Phase II lipodystrophy study was halted after a participant death that the attending physician attributed to pre-existing coronary disease rather than the drug. Overall, the supplied evidence supports short-term pharmacology signals but does not establish long-term safety, clinical efficacy, approval, or the implications of chronic IGF-1 elevation.